Asthma and COPD patients in the UK are set to receive faster, community-based care under a £10 million NHS initiative, ...

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

Zydus Lifesciences Limited, an innovation-led life-sciences company with an international presence, has launched Aerolife ...

Asthma and chronic obstructive pulmonary disease patients will receive better care closer to home under a landmark £10million partnership Care for ...

Patients with COPD and heart failure treated with SGLT-2 inhibitors experienced higher rates of volume depletion and adverse renal events. Chronic obstructive pulmonary disease (COPD) reduces the ...

Individuals with chronic obstructive pulmonary disease (COPD) with coexisting obstructive sleep apnea (OSAS) have greater ...

Reinventing pulmonary care medically improves early diagnosis and interdisciplinary management for complex patients with COPD and co-morbidities.

Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Cl ...

Patients living with asthma and chronic obstructive pulmonary disease (COPD) will receive faster, better and more personalised care under a landmark new programme to tackle one of the leading causes ...

Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD exacerbation with a dry powder inhaler vs. a metered-dose or soft mist ...